(Q37686069)

22 August 2017

1 reference

title

Immunotherapy of myositis: issues, concerns and future prospects (English)

1 reference

22 August 2017

1 reference

1 reference

Marinos C Dalakas

1

1 reference

PubMed ID

20125096

22 August 2017

language of work or name

English

0 references

publication date

2 February 2010

1 reference

Nature Reviews Rheumatology

22 August 2017

1 reference

22 August 2017

6

1 reference

22 August 2017

3

1 reference

22 August 2017

129-137

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2010.2

22 August 2017

0 references

cites work

Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Differential expression of chemokines in inflammatory myopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Intravenous immunoglobulin for dysphagia of inclusion body myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Polymyositis, dermatomyositis and inclusion-body myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Polymyositis and dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Inclusion body myositis: new concepts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Sporadic inclusion body myositis: a continuing puzzle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Inclusion body myositis and myopathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Toxic and drug-induced myopathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Expression of immunoreactive major histocompatibility complex products in human skeletal muscles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Therapeutic approaches in patients with inflammatory myopathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Microvascular deposition of complement membrane attack complex in dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Microvascular changes in early and advanced dermatomyositis: a quantitative study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Immunopathogenesis of inflammatory myopathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Expression of cell adhesion molecules in inflammatory myopathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Immunobiology of muscle: advances in understanding an immunological microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Autoantibodies and their significance in myositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Prednisone and azathioprine for polymyositis: long-term followup.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Treatment of inflammatory myopathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Immunoglobulin therapy in inflammatory myopathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Intravenous immunoglobulin in autoimmune neuromuscular diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

B cells as therapeutic targets in autoimmune neurological disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Rituximab in the treatment of dermatomyositis: an open-label pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

A pilot trial of rituximab in the treatment of patients with dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Tacrolimus in refractory polymyositis with interstitial lung disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Basic principles of immunotherapy for neurologic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Idiopathic inflammatory myopathies: current and future therapeutic options.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Refractory polymyositis responding to infliximab: extended follow-up.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Interplay between inflammation and degeneration: using inclusion body myositis to study "neuroinflammation"

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Safety and efficacy of strength training in patients with sporadic inclusion body myositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.2

Pathology of the inflammatory myopathies

31 March 2020

1 reference

12 December 2020

Signal transducer and activator of transcription 1 in human muscle: implications in inflammatory myopathies

1 reference

12 December 2020

[Current therapy for polymyositis and dermatomyositis]

1 reference

12 December 2020

Current treatment of the inflammatory myopathies

1 reference

12 December 2020

Alemtuzumab (Campath-1H) for treatment of refractory polymyositis

1 reference

12 December 2020

Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2010.2

1 reference

PubMed ID

20125096

Dimensions Publication ID

22 August 2017

0 references

1 reference

PubMed ID

20125096